Vical Incorporated Company Profile (NASDAQ:VICL)

About Vical Incorporated (NASDAQ:VICL)

Vical Incorporated logoVical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of life-threatening diseases. The Company has approximately four active, independent, or partnered development programs in the areas of infectious disease including Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients; an ongoing Phase I program of VL-2397 for invasive fungal infections, and completed preclinical program, with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:VICL
  • CUSIP: 92560210
  • Web:
  • Market Cap: $27.52 million
  • Outstanding Shares: 11,096,000
Average Prices:
  • 50 Day Moving Avg: $2.32
  • 200 Day Moving Avg: $2.27
  • 52 Week Range: $2.05 - $4.61
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.23
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $13.13 million
  • Price / Sales: 2.07
  • Book Value: $3.84 per share
  • Price / Book: 0.64
  • EBIDTA: ($8,100,000.00)
  • Net Margins: -71.38%
  • Return on Equity: -21.06%
  • Return on Assets: -18.62%
  • Current Ratio: 5.33%
  • Quick Ratio: 5.33%
  • Average Volume: 82,402 shs.
  • Beta: 2.25
  • Short Ratio: 1.16

Frequently Asked Questions for Vical Incorporated (NASDAQ:VICL)

What is Vical Incorporated's stock symbol?

Vical Incorporated trades on the NASDAQ under the ticker symbol "VICL."

How were Vical Incorporated's earnings last quarter?

Vical Incorporated (NASDAQ:VICL) posted its quarterly earnings results on Monday, May, 15th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.18) by $0.07. The business earned $3.21 million during the quarter. Vical Incorporated had a negative net margin of 71.38% and a negative return on equity of 21.06%. View Vical Incorporated's Earnings History.

Where is Vical Incorporated's stock going? Where will Vical Incorporated's stock price be in 2017?

2 analysts have issued 1 year price targets for Vical Incorporated's shares. Their predictions range from $9.00 to $9.00. On average, they anticipate Vical Incorporated's stock price to reach $9.00 in the next twelve months. View Analyst Ratings for Vical Incorporated.

Who are some of Vical Incorporated's key competitors?

Who are Vical Incorporated's key executives?

Vical Incorporated's management team includes the folowing people:

  • R. Gordon Douglas M.D., Independent Chairman of the Board
  • Vijay B. Samant, President, Chief Executive Officer, Director
  • Anthony Alan Ramos, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
  • Mammen P. Mammen Jr., Vice President - Clinical Vaccines
  • Lawrence Russell Smith, Vice President - Vaccine Research
  • Thomas E. Shenk Ph.D., Director
  • Richard M. Beleson, Independent Director
  • Gary A. Lyons, Independent Director
  • Robert C. Merton Ph.D., Independent Director
  • George J. Morrow, Independent Director

Who owns Vical Incorporated stock?

Vical Incorporated's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (0.00%), Renaissance Technologies LLC (0.00%), Ariel Investments LLC (0.00%) and Vanguard Group Inc. (0.00%). Company insiders that own Vical Incorporated stock include Anthony Alan Ramos, Gary A Lyons, Igor Bilinsky, Lawrence Russell Smith, R Gordon Douglas, Robert C Merton and Vijay B Samant. View Institutional Ownership Trends for Vical Incorporated.

Who sold Vical Incorporated stock? Who is selling Vical Incorporated stock?

Vical Incorporated's stock was sold by a variety of institutional investors in the last quarter, including Ariel Investments LLC and FMR LLC. Company insiders that have sold Vical Incorporated stock in the last year include Anthony Alan Ramos, Lawrence Russell Smith, R Gordon Douglas, Robert C Merton and Vijay B Samant. View Insider Buying and Selling for Vical Incorporated.

Who bought Vical Incorporated stock? Who is buying Vical Incorporated stock?

Vical Incorporated's stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Vanguard Group Inc.. Company insiders that have bought Vical Incorporated stock in the last two years include Gary A Lyons, R Gordon Douglas, Robert C Merton and Vijay B Samant. View Insider Buying and Selling for Vical Incorporated.

How do I buy Vical Incorporated stock?

Shares of Vical Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vical Incorporated's stock price today?

One share of Vical Incorporated stock can currently be purchased for approximately $2.45.

MarketBeat Community Rating for Vical Incorporated (NASDAQ VICL)
Community Ranking:  3.2 out of 5 (  )
Outperform Votes:  67 (Vote Outperform)
Underperform Votes:  39 (Vote Underperform)
Total Votes:  106
MarketBeat's community ratings are surveys of what our community members think about Vical Incorporated and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Vical Incorporated (NASDAQ:VICL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.00 (267.35% upside)

Analysts' Ratings History for Vical Incorporated (NASDAQ:VICL)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/12/2017HC WainwrightSet Price TargetBuy$9.00LowView Rating Details
6/12/2017Rodman & RenshawReiterated RatingBuy -> Buy$9.00HighView Rating Details
(Data available from 6/24/2015 forward)


Earnings History for Vical Incorporated (NASDAQ:VICL)
Earnings by Quarter for Vical Incorporated (NASDAQ:VICL)
Earnings History by Quarter for Vical Incorporated (NASDAQ VICL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/2017Q1 2017($0.18)($0.25)$3.21 millionViewN/AView Earnings Details
3/9/2017Q4 2016($0.21)($0.25)$2.92 million$3.16 millionViewListenView Earnings Details
11/3/2016Q3($0.25)($0.24)$4.60 million$2.60 millionViewN/AView Earnings Details
8/9/2016Q216($0.28)($0.14)$4.50 million$4.10 millionViewN/AView Earnings Details
5/9/2016Q116($0.04)($0.03)$6.88 million$4.60 millionViewN/AView Earnings Details
3/14/2016Q415($0.02)($0.03)$4.82 million$6.81 millionViewListenView Earnings Details
7/30/2015Q215($0.06)($0.03)$3.80 million$4.20 millionViewListenView Earnings Details
5/8/2015Q115($0.05)($0.04)$2.50 million$4.90 millionViewN/AView Earnings Details
2/26/2015Q414($0.05)($0.05)$3.58 million$4.82 millionViewN/AView Earnings Details
10/30/2014Q314($0.05)($0.05)$2.50 million$3.40 millionViewN/AView Earnings Details
7/31/2014Q214($0.05)($0.05)$1.90 million$4.50 millionViewN/AView Earnings Details
5/1/2014Q114($0.05)($0.04)$1.60 million$2.40 millionViewN/AView Earnings Details
2/11/2014Q413($0.09)($0.03)$1.54 million$3.15 millionViewN/AView Earnings Details
10/31/2013Q313($0.10)($0.11)$1.82 million$1.50 millionViewN/AView Earnings Details
8/1/2013Q2 2013($0.11)($0.11)$1.70 million$3.00 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.11)($0.11)$2.02 million$1.60 millionViewN/AView Earnings Details
2/6/2013Q4 2012($0.10)($0.09)$1.64 million$2.32 millionViewN/AView Earnings Details
11/7/2012Q312($0.09)($0.09)$1.47 million$2.20 millionViewN/AView Earnings Details
8/1/2012($0.09)($0.09)ViewN/AView Earnings Details
11/1/2011$0.11$0.22ViewN/AView Earnings Details
8/3/2011($0.12)($0.12)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Vical Incorporated (NASDAQ:VICL)
Current Year EPS Consensus Estimate: $-1.1 EPS
Next Year EPS Consensus Estimate: $-1.1 EPS


Dividend History for Vical Incorporated (NASDAQ:VICL)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Vical Incorporated (NASDAQ:VICL)
Insider Ownership Percentage: 5.98%
Institutional Ownership Percentage: 23.65%
Insider Trades by Quarter for Vical Incorporated (NASDAQ:VICL)
Institutional Ownership by Quarter for Vical Incorporated (NASDAQ:VICL)
Insider Trades by Quarter for Vical Incorporated (NASDAQ:VICL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/27/2017Anthony Alan RamosVPSell4,250$2.17$9,222.50View SEC Filing  
1/11/2017Lawrence Russell SmithVPSell54$2.48$133.92View SEC Filing  
1/10/2017Vijay B. SamantCEOSell5,763$2.45$14,119.35View SEC Filing  
12/22/2016Robert C. MertonDirectorSell4,000$2.24$8,960.00View SEC Filing  
12/20/2016Robert C. MertonDirectorSell4,327$2.21$9,562.67View SEC Filing  
12/13/2016Vijay B. SamantCEOSell15,699$2.39$37,520.61View SEC Filing  
12/12/2016R Gordon DouglasDirectorSell10,078$2.39$24,086.42View SEC Filing  
10/11/2016Lawrence Russell SmithVPSell54$3.05$164.70View SEC Filing  
7/11/2016Lawrence Russell SmithVPSell54$4.46$240.84View SEC Filing  
6/14/2016Robert C MertonDirectorBuy9,000$4.34$39,060.00View SEC Filing  
6/9/2016Vijay B SamantCEOBuy15,700$4.72$74,104.00View SEC Filing  
6/6/2016R Gordon DouglasDirectorBuy10,078$4.41$44,443.98View SEC Filing  
6/3/2016Gary A LyonsDirectorBuy7,078$4.39$31,072.42View SEC Filing  
3/15/2016Lawrence Russell SmithVPSell8,750$0.41$3,587.50View SEC Filing  
3/3/2016Vijay B SamantCEOSell37,500$0.36$13,500.00View SEC Filing  
2/19/2016Anthony Alan RamosCAOSell7,500$0.33$2,475.00View SEC Filing  
1/25/2016Anthony Alan RamosCAOSell193$0.35$67.55View SEC Filing  
1/12/2016Vijay B. SamantCEOSell59,737$0.35$20,907.95View SEC Filing  
1/11/2016Lawrence Russell SmithVPSell974$0.36$350.64View SEC Filing  
1/11/2016Vijay B. SamantCEOSell48,535$0.35$16,987.25View SEC Filing  
1/7/2016Vijay B SamantCEOSell75,000$0.36$27,000.00View SEC Filing  
10/12/2015Lawrence Russell SmithVPSell974$0.43$418.82View SEC Filing  
10/12/2015Vijay B SamantCEOSell4,738$0.41$1,942.58View SEC Filing  
7/13/2015Igor BilinskySVPSell1,258$0.70$880.60View SEC Filing  
7/13/2015Lawrence Russell SmithVPSell974$0.70$681.80View SEC Filing  
7/13/2015Vijay B SamantCEOSell4,737$0.70$3,315.90View SEC Filing  
4/13/2015Igor BilinskySVPSell1,257$0.93$1,169.01View SEC Filing  
4/13/2015Vijay B SamantCEOSell4,738$0.93$4,406.34View SEC Filing  
3/30/2015Vijay B SamantCEOSell55,000$0.91$50,050.00View SEC Filing  
1/13/2015Vijay B SamantCEOSell4,737$1.12$5,305.44View SEC Filing  
1/12/2015Igor BilinskySVPSell1,335$1.16$1,548.60View SEC Filing  
1/12/2015Lawrence Russell SmithVPSell1,912$1.16$2,217.92View SEC Filing  
10/13/2014Igor BilinskySVPSell1,335$1.08$1,441.80View SEC Filing  
10/13/2014Lawrence Russell SmithVPSell1,912$1.08$2,064.96View SEC Filing  
10/13/2014Vijay B SamantCEOSell4,738$1.13$5,353.94View SEC Filing  
8/26/2014Anthony Alan RamosCAOSell12,500$1.25$15,625.00View SEC Filing  
7/14/2014Vijay B SamantCEOSell4,737$1.17$5,542.29View SEC Filing  
7/11/2014Lawrence Russell SmithVPSell1,912$1.16$2,217.92View SEC Filing  
4/14/2014Vijay SamantCEOSell4,738$1.16$5,496.08View SEC Filing  
4/11/2014Lawrence Russell SmithVPSell1,912$1.21$2,313.52View SEC Filing  
1/10/2014Anthony Alan RamosCAOBuy70,000$1.42$99,400.00View SEC Filing  
1/10/2014Igor BilinskyVPBuy90,000$1.42$127,800.00View SEC Filing  
1/10/2014Vijay SamantCEOBuy330,000$1.42$468,600.00View SEC Filing  
9/12/2013James R SingerMajor ShareholderSell200,000$1.29$258,000.00View SEC Filing  
9/11/2013James R SingerMajor ShareholderSell300,000$1.30$390,000.00View SEC Filing  
9/10/2013James R SingerMajor ShareholderSell200,000$1.23$246,000.00View SEC Filing  
9/9/2013James R SingerMajor ShareholderSell200,000$1.22$244,000.00View SEC Filing  
9/4/2013James Singermajor shareholderSell466,000$1.24$577,840.00View SEC Filing  
8/30/2013James Singermajor shareholderSell84,000$1.31$110,040.00View SEC Filing  
8/29/2013James Singermajor shareholderSell150,000$1.30$195,000.00View SEC Filing  
8/28/2013James Singermajor shareholderSell200,000$1.31$262,000.00View SEC Filing  
8/26/2013Anthony Alan RamosCAOBuy25,000$0.01$250.00View SEC Filing  
5/23/2013Robert C MertonDirectorBuy5,953$0.01$59.53View SEC Filing  
1/11/2013Alain P Phd RollandVPBuy22,092$0.01$220.92View SEC Filing  
1/11/2013Jill Marie BroadfootCFOBuy27,060$0.01$270.60View SEC Filing  
1/11/2013Vijay B SamantCEOBuy84,600$0.01$846.00View SEC Filing  
10/15/2012George J MorrowDirectorBuy6,394$0.01$63.94View SEC Filing  
9/24/2012James R SingerMajor ShareholderBuy154,333$3.99$615,788.67View SEC Filing  
8/31/2012James R SingerMajor ShareholderBuy310,000$3.51$1,088,100.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Vical Incorporated (NASDAQ:VICL)
Latest Headlines for Vical Incorporated (NASDAQ:VICL)
DateHeadline logoVical to Provide Company Update at the 2017 BIO International Convention - June 15 at 8:52 PM logoETFs with exposure to Vical, Inc. : June 14, 2017 - June 15 at 4:00 AM logoVical, Inc. :VICL-US: Earnings Analysis: Q1, 2017 By the Numbers : June 13, 2017 - June 14 at 1:32 AM logoVical Incorporated (VICL) PT Set at $9.00 by HC Wainwright - June 13 at 2:12 PM logoVical Incorporated (VICL) Research Coverage Started at Rodman & Renshaw - June 12 at 4:20 PM logoVical Presents Phase 1 VL-2397 Data at the June ASM Microbe 2017 Meeting Supporting Advancement to Phase 2 - June 5 at 11:09 AM logoVical to Present VL-2397 Data at the June ASM Microbe 2017 Meeting - May 23 at 7:09 AM logoVical Incorporated (VICL) Announces Quarterly Earnings Results - May 16 at 2:58 PM logoEdited Transcript of VICL earnings conference call or presentation 15-May-17 4:00pm GMT - May 16 at 8:22 AM logoInvestor Network: Vical Incorporated to Host Earnings Call - May 15 at 7:40 PM logoVical Reports First Quarter 2017 Financial Results - May 15 at 8:35 AM logoVical reports 1Q loss - May 15 at 8:35 AM logoVical misses by $0.07, misses on revenue - May 15 at 6:43 AM logoVical revenues off 30% in Q1 - May 15 at 6:43 AM logoInvestor Network Invites You to the Vical First Quarter 2017 Earnings Webcast Live on Monday, May 15, 2017 - May 13 at 2:41 AM logoVical Announces News Release and Conference Call Schedule for First Quarter 2017 Financial Results - May 8 at 7:07 AM logoVical Incorporated (VICL) to Release Earnings on Monday - May 6 at 7:04 AM logoVical Highlights Successful Outcome of Phase 1 Trial of VL-2397 Novel Antifungal During its Research and Development Day - May 2 at 6:36 PM logoVical (VICL) Earning Somewhat Negative News Coverage, Analysis Finds - April 30 at 9:02 AM logoVical to Host Virtual Research & Development Day on May 2, 2017 - April 24 at 9:18 AM logoVical (VICL) Given Daily Media Sentiment Rating of 0.56 - April 23 at 9:29 AM logoVical (VICL) Finalizes Target Enrollment for Phase 2 Therapeutic HSV-2 Vaccine Trial - April 21 at 12:07 AM logoVical Completes Target Enrollment in Its Phase 2 Therapeutic HSV-2 Vaccine Trial - April 19 at 8:23 AM logoVical (VICL) Earns Media Sentiment Rating of 0.22 - April 16 at 9:51 AM logoETFs with exposure to Vical, Inc. : April 5, 2017 - April 7 at 1:21 PM logo Vical Incorporated (VICL) Given Average Recommendation of "" by Analysts - March 21 at 10:49 AM logoVICAL INC Financials - March 16 at 3:26 PM logoVICAL INC Files SEC form 10-K, Annual Report - March 11 at 10:10 AM logoVical's (VICL) CEO Vijay Samant on Q4 2016 Results - Earnings Call Transcript - March 10 at 9:57 AM logoVical to Provide Company Update at the 29th Annual ROTH Conference - March 10 at 7:27 AM logoVical Reports Fourth Quarter 2016 Financial Results - March 9 at 11:17 PM logoVical to Provide Company Update at BIO Asia International Conference - March 9 at 11:17 PM logoQ4 2016 Vical Inc Earnings Release - Before Market Open - March 9 at 11:17 PM logoVICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - March 9 at 11:17 PM logoVical misses by $0.04, misses on revenue - March 9 at 6:49 AM logoInvestor Network Invites You to the Vical Fourth Quarter 2016 Earnings Webcast Live on Thursday, March 9, 2017 - March 9 at 4:14 AM logoVical Announces News Release and Conference Call Schedule for Fourth Quarter 2016 Financial Results - March 3 at 5:22 AM logoVical Provides Company Update at Biocom's Global Life Science Partnering Conference - February 24 at 4:20 PM logoVical Provides Company Update at BIO CEO and Investor Conference - February 7 at 3:32 PM



Vical Incorporated (VICL) Chart for Saturday, June, 24, 2017

This page was last updated on 6/24/2017 by Staff